<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02981368</url>
  </required_header>
  <id_info>
    <org_study_id>PyL 2301</org_study_id>
    <nct_id>NCT02981368</nct_id>
  </id_info>
  <brief_title>Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer</brief_title>
  <acronym>OSPREY</acronym>
  <official_title>A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Progenics Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Progenics Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in
      patients with at least high risk prostate cancer who are planned for radical prostatectomy
      with lymphadenectomy (Cohort A) or in patients with locally recurrent or metastatic disease
      willing to undergo biopsy (Cohort B).

      Cohort B is complete and no longer recruiting subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and Specificity of 18F-DCFPyL PET/CT imaging to detect metastatic prostate cancer within the pelvic lymph nodes relative to histopathology in Cohort A</measure>
    <time_frame>Within 1-2 hours of dosing, whole body PET/CT scan will be taken. Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in clinical laboratory values [Safety and Tolerability]</measure>
    <time_frame>From time of screening until pre-surgery/biopsy (within 28 days post-study drug dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ECG related to 18F-DCFPyL administration [Safety and Tolerability]</measure>
    <time_frame>Changes in ECG pre-drug dosing and within 1-2 hours post-dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment emergent adverse events [Safety and Tolerability]</measure>
    <time_frame>From study drug dosing until 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of 18F-DCFPyL PET/CT imaging to detect prostate cancer within sites of metastasis or local recurrence relative to histopathology in Cohort B</measure>
    <time_frame>Within 1-2 hours of dosing, whole body PET/CT scan will be taken. Within 28 days of imaging, biopsy will occur.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion count in different locations as detected by 18F-DCFPyL vs. conventional imaging</measure>
    <time_frame>Within 1-2 hours of dosing, whole body PET/CT scan will be taken</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and negative predictive values (PPV and NPV) of 18F-DCFPyL PET/CT imaging to predict prostate cancer within the prostate gland and lymph nodes in Cohort A</measure>
    <time_frame>Within 1-2 hours of dosing, whole body PET/CT scan will be taken. Within 28 days of imaging, radical prostatecomy with pelvic lymph node dissection will occur.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PPV of 18F-DCFPyL PET/CT imaging to predict prostate cancer within sites of local recurrence and other metastatic lesions in Cohort B</measure>
    <time_frame>Within 1-2 hours of dosing, whole body PET/CT scan will be taken. Within 28 days of imaging, biopsy will occur.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) of 18F-DCFPyL in subset of patients</measure>
    <time_frame>At 0-8 hours post- dosing</time_frame>
    <description>Summary statistics by timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration vs time curve (AUC) of 18F-DCFPyL in subset of patients</measure>
    <time_frame>At 0-8 hours post- dosing</time_frame>
    <description>Summary statistics by timepoint</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory analysis of 18F-DCFPyL uptake in different lesion locations</measure>
    <time_frame>Within 1-2 hours of dosing, whole body PET/CT scan will be taken</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pre-specified post hoc retrospective analysis of changes to clinical management plan based on central expert panel review of clinical and radiographic subject data before and after 18F-DCFPyL PET/CT scan results</measure>
    <time_frame>After enrollment is complete</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">377</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>18F-DCFPyL Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-DCFPyL Injection</intervention_name>
    <description>A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL</description>
    <arm_group_label>18F-DCFPyL Injection</arm_group_label>
    <other_name>PyL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed adenocarcinoma of the prostate.

          2. Subjects provide signed informed consent and confirm that they are able and willing to
             comply with all protocol requirements.

        Cohort A Only:

          -  At least high risk prostate cancer defined by NCCN Guidelines Version 3.2016 (clinical
             stage ≥T3a or PSA &gt;20 ng/mL or Gleason score ≥8).

          -  Scheduled or planned radical prostatectomy with PLND.

        Cohort B Only: [Enrollment is complete; No longer recruiting subjects]

          -  Radiologic evidence of local recurrence or new or progressive metastatic disease
             demonstrated on anatomical imaging (CT, MRI, or ultrasound), whole-body bone scan
             (99m-Tc-MDP or Na-18F) within 4 weeks of enrollment.

          -  If prior treatment with radiation or ablative therapy, evidence of recurrence outside
             the confines of prior treated site(s) is needed.

          -  Scheduled or planned percutaneous biopsy of at least one amenable lesion.

        Exclusion Criteria:

          1. Subjects administered any high energy (&gt;300 KeV) gamma-emitting radioisotope within
             five physical half-lives, or any IV iodinated contrast medium within 24 hours, or any
             high density oral contrast medium (oral water contrast is acceptable) within 5 days,
             prior to study drug injection.

          2. Subjects with any medical condition or other circumstance that, in the opinion of the
             investigator, compromise obtaining reliable data, achieving study objectives, or
             completion.

        Cohort A Only:

          -  Patients with prior androgen deprivation therapy or any investigational neoadjuvant
             agent or intervention

        Cohort B Only: [Enrollment is Complete; No longer recruiting subjects]

          -  Prior radiation or ablative therapy to intended site of biopsy, if within the prostate
             bed

          -  Initiation of new therapy for recurrent and/or progressive metastatic disease since
             radiographic documentation of recurrence/progression.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Morris, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth J Pienta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Strack, MD</last_name>
    <phone>646-975-2518</phone>
    <email>tstrack@progenics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Theresa White</last_name>
    <phone>646-975-2554</phone>
    <email>twhite@progenics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California at San Francisco (UCSF) - Mt. Zion Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imelda Tenggara</last_name>
      <phone>415-353-7348</phone>
      <email>imelda.tenggara@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Carroll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University Department of Radiology and Biomedical Imaging</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Vassilieva</last_name>
      <phone>203-785-5182</phone>
      <email>svetlana.vassilieva@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Lawrence Saperstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Preston Sprenkle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Petrylak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benas Jakubauskas</last_name>
      <phone>773-702-3498</phone>
    </contact>
    <investigator>
      <last_name>Akash Patnaik, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narineh Abrahamian</last_name>
      <phone>443-287-7790</phone>
      <email>nabrah10@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Pienta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Gorin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha J Salvucci</last_name>
      <phone>617-732-5153</phone>
      <email>SJSalvucci@Partners.org</email>
    </contact>
    <investigator>
      <last_name>Mark Preston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Center Hotline</last_name>
      <phone>800-865-1125</phone>
      <email>canceranswerline@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Ajjia Alva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Mallinckrodt Institute of Radilogy</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Frye</last_name>
      <phone>314-747-1604</phone>
      <email>fryej@mir.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anna Self</last_name>
      <phone>314-362-2916</phone>
      <email>aself@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Barry Siegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerald Andriole, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Parada</last_name>
      <phone>646-227-2160</phone>
      <email>paradan@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Mike Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Probst, MD</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>4181</phone_ext>
      <email>nukesmd@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Gad Abikhzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Probst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec (CHUQ)</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria-Margarita Becerra-Perez</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>21623</phone_ext>
      <email>maria-margarita.becerra-perez@crchudequebec.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Frederic Pouliot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diagnostic</keyword>
  <keyword>Imaging</keyword>
  <keyword>2301</keyword>
  <keyword>PET/CT</keyword>
  <keyword>PyL</keyword>
  <keyword>PSMA</keyword>
  <keyword>radical prostatectomy</keyword>
  <keyword>metastatic prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

